

1 **Signal complexity indicators of health status in clinical-EEG**

2 **Kelly Shen^{1*}, Alison McFadden¹, Anthony R. McIntosh^{1,2}**

3 ¹Rotman Research Institute, Baycrest Centre

4 ²University of Toronto

5 *Corresponding Author

6 Email: kshen@research.baycrest.org

7 Mailing Address:

8 3560 Bathurst Street

9 Toronto ON M6A 2E1

10 Canada

11 **Abstract**

12 Brain signal variability changes across the lifespan in both health and disease, likely
13 reflecting changes in information processing capacity related to development, aging and
14 neurological disorders. While signal complexity, and multiscale entropy (MSE) in particular,
15 has been proposed as a biomarker for neurological disorders, most observations of altered
16 signal complexity have come from studies comparing patients with few to no comorbidities
17 against healthy controls. In this study, we examined whether MSE of brain signals was
18 distinguishable across individuals in a large and heterogeneous set of clinical-EEG data.
19 Using a multivariate analysis, we found unique timescale-dependent differences in MSE
20 across various neurological disorders. We also found MSE to differentiate individuals with
21 non-brain comorbidities, suggesting that MSE is sensitive to brain signal changes brought
22 about by metabolic and other non-brain disorders. Such changes were not detectable in the
23 spectral power density of brain signals. Our findings suggest that brain signal complexity
24 may offer complementary information to spectral power about an individual's health status
25 and is a promising avenue for clinical biomarker development.

26 **Keywords:** Multi-scale entropy, EEG, neurodegenerative disease, epilepsy

27 **Introduction**

28 A growing literature suggests that some degree of brain signal variability is vital to optimal
29 brain function. Although seemingly paradoxical, noisy (or complex) brain signals are related
30 to a greater capacity for information processing as compared to more predictable signals
31 (Garrett et al., 2018; Vakorin and McIntosh, 2012). Sample entropy is one way to capture the
32 variability of a brain signal (Richman and Moorman, 2000) and multiscale entropy (MSE),
33 where complexity is examined across multiple timescales (Costa et al., 2005), has been
34 particularly useful in broadening our understanding of the role of noise in brain health and
35 disease. MSE, like other measures of entropy, captures the variability in a signal but can
36 additionally differentiate variability induced by increasing randomness, such that white
37 noise gives lower MSE values (Costa et al., 2005). An increase in MSE has been observed in
38 tasks requiring memory retrieval (Heisz et al., 2012) or the integration of stimulus features
39 (Misić et al., 2010) and seems to support accurate and stable behavior (Misić et al., 2010;
40 Raja Beharelle et al., 2012). MSE has been shown to have timescale-dependent shifts during
41 brain development (Hasegawa et al., 2018; Lippé et al., 2009; Miskovic et al., 2016;
42 Szostakiwskyj et al., 2017) and aging (McIntosh et al., 2014; Sleimen-Malkoun et al., 2015; H.
43 Wang et al., 2016) that supports cognitive function (Heisz et al., 2015; Yang et al., 2013),
44 reflecting changes in the brain's information processing capacity across the lifespan. MSE
45 also reflects processing capacity changes related to various brain diseases including
46 dementia (Bertrand et al., 2016; Grieder et al., 2018; Niu et al., 2018), neurodevelopmental
47 disorders (Mišić et al., 2015; Takahashi et al., 2016; Weng et al., 2017), and psychiatric
48 disorders (Hager et al., 2017; Takahashi, 2013; Yang et al., 2015).

49 In nearly all of these studies, brain signal complexity changes related to various brain
50 diseases have been detected by comparing individuals with few to no comorbidities against
51 matched healthy controls using data collected in highly controlled laboratory environments.
52 While MSE has been proposed for use as a clinical biomarker for various neurological
53 disorders (Jeste et al., 2015; Lu et al., 2015; Tsai et al., 2015), whether differences in brain
54 signal complexity can be detected across individuals of a heterogenous clinical population
55 per se remains unknown. In this study, we leveraged the Temple University Corpus EEG
56 database (Obeid and Picone, 2016) to test the utility of MSE as an indicator of health status
57 in a large and heterogeneous clinical population. We found MSE of clinical-EEG signals
58 differentiated individuals of varying brain disorders. Interestingly, we also found MSE to
59 differentiate between individuals with non-brain comorbidities and those without
60 comorbidities.

61 **Methods**

62 **Subjects**

63 Clinical EEG data and corresponding physician reports were downloaded from the Temple
64 University Hospital EEG Epilepsy Corpus (v0.0.1) containing 100 subjects deemed to have
65 epilepsy and 100 subjects without epilepsy
66 (https://www.isip.piconepress.com/projects/tuh_eeg/) (Obeid and Picone, 2016). Subjects
67 from the epilepsy group were included in our sample if the report indicated a previous
68 diagnosis of epilepsy, if the EEG supported a diagnosis of epilepsy, or if the patient had
69 experienced 2 or more unprovoked seizures occurring more than 24 hours apart and the
70 EEG did not contraindicate epilepsy. Subjects without epilepsy were included if they did not
71 meet any of these criteria. Subjects from either group were excluded if a seizure occurred
72 during the recording, if the subject's level of consciousness was decreased, or if the subject
73 was under the effect of a device likely to cause substantial EEG artifact such as a pacemaker
74 or ventilator. Subjects were also excluded if their recordings were deemed unsuitable in the
75 preprocessing stage due to the presence of artifacts.

76 Demographic and clinical characteristics were extracted from the physician reports
77 (Table 1). For the various brain-acting medications (anti-epileptic drugs, barbiturates,
78 benzodiazepines, antipsychotics, and antidepressants), subjects were considered to be on
79 them if their medication list included at least one medication of that category. The total
80 number of other (i.e., not brain-acting) medications for each subject was computed by
81 counting the number of total medications listed for the subject and subtracting the number
82 of medications that fell into the brain-acting medication categories listed above. If the

83 medication list stated “others” or a pluralized general category of medications (i.e.
84 “antihypertensives”), two medications were added to the non-brain medication count. Most
85 of the non-brain acting medications reported (69.3%; 223/322) are those used to treat
86 cardiovascular disease, diabetes or chronic respiratory illness. Seizure classifications and
87 terms were determined as outlined by the International League Against Epilepsy (Berg et al.,
88 2010; Blume et al., 2001). A subject was considered to have experienced generalized or focal
89 seizures if their physician’s report contained either a diagnosis falling in one of those
90 categories or a description of seizures matching the expected presentation for that seizure
91 classification. Thirty-four subjects experienced seizures of unknown classification and were
92 excluded from analysis. A further 3 subjects did not have age or sex information available
93 and were also excluded from analysis. This resulted in a total sample size of 163 subjects.
94 Accepted phrases for stroke included indication of a past or present ischemic stroke,
95 hemorrhagic stroke, “CVA”, or intracerebral bleed. Accepted diagnoses for degenerative
96 brain diseases included Alzheimer’s disease, Parkinson’s disease, and dementia. Accepted
97 diagnoses for psychiatric disorders included anxiety, depression, bipolar disease, and
98 schizophrenia. Accepted diagnoses for neurodevelopmental disorders included Down’s
99 syndrome, ADHD, intellectual disabilities, and cerebral palsy. Finally, other brain disorders
100 and injuries included head trauma, brain surgery, brain cancer or metastases, hypoxic brain
101 injuries, encephalitis and meningitis.

102 **Table 1. Demographic and clinical characteristics of study sample.**

<i>Variables</i>	<i>Subjects (n=163)</i>
Age, mean (SD, range)	52.12 (19.88, 7-91)
Sex, n female (%)	91 (55.83)
<i>Medication use</i>	
Anti-epileptic drug use, %	36.2
Barbiturate use, %	2.45
Benzodiazepine use, %	11.04
Antipsychotic use, %	9.82
Antidepressant use, %	11.04
Other medications, mean (SD, range)	2.26 (2.75, 0-13)
<i>Past medical history</i>	
Diagnosis of epilepsy, %	40.49
History of stroke, %	19.02
Diagnosed degenerative brain disease, %	4.91
Diagnosed psychiatric disorder, %	12.27
Diagnosed neurodevelopmental disorder, %	3.68
Other brain disorder or injury, %	16.56

103 **EEG preprocessing & analysis**

104 Each subject contributed one EEG recording. For subjects with multiple recordings, the
105 recording corresponding to the physician report containing the most complete clinical
106 picture was selected. For recordings that were split into multiple segments, the longest of
107 the segments was chosen for preprocessing. All preprocessing was performed using the
108 FieldTrip toolbox in MATLAB (www.fieldtriptoolbox.org) (Oostenveld et al., 2011). For each
109 selected recording, 19 scalp electrodes of the International 10-20 system that were common
110 to all subjects were selected. The resulting continuous recordings were segmented into 4-s
111 trials, producing an average of 317 trials per subject, and bandpass filtered (0.5 to 55 Hz).
112 The majority of recordings were sampled at 250 Hz, but one subject that was sampled at 512
113 Hz was downsampled to 250 Hz before proceeding.

114 Two trial removal steps were then completed. The majority of subjects received
115 photic stimulation. For these subjects, trials where photic stimulation began and ended were
116 detected, and the trials within this range to 5 trials past the end of stimulation were removed.
117 Trials at the beginning of a recording where the amplitude of the photic channel was not zero
118 were also removed. Next, trials with excessive signal amplitude were detected for removal.
119 For each subject, 30% of the trials that were determined by visual inspection to be
120 reasonably free of artifacts were selected. Global field power was calculated and its mean \pm
121 5 std was used to reject trials with time points outside of this threshold. The average number
122 of remaining trials per subject following both of these removal steps was 178.

123 Independent component analysis was next used to remove ocular and muscle
124 artifacts. Components with topographical distributions typical of these artifacts were
125 selected and their traces further examined. Where possible, probable ocular artifact
126 components were confirmed via alignment of the component trace with the
127 electrooculogram traces from the original recording. Probable muscle artifact components
128 were confirmed by the presence of a high frequency component trace. Finally, any recordings
129 not referenced to a common average were re-referenced.

130 MSE (Costa et al., 2005, 2002) was computed by first coarse-graining the EEG time
131 series of each trial into 20 scales. To produce the time series coinciding with a given scale t ,
132 data points from the original time series within non-overlapping windows of length t were
133 averaged. Thus scale 1 represents the original time series, with 1000 data points per channel
134 per trial resulting from 4 seconds of recording sampled at 250 Hz. Next, sample entropy was
135 calculated for each time series across all scales. This measured the predictability of the
136 amplitude between two versus three consecutive data points ($m=2$), with the condition that

137 data points were considered to have indistinguishable amplitude from one another if the
138 absolute difference in amplitude between them was $\leq 50\%$ of the standard deviation of the
139 time series ($r = 0.5$). The resulting values were averaged across trials to produce a single
140 MSE curve per channel for each subject. As an entropy-based measure, MSE values are low
141 for both completely deterministic as well as completely uncorrelated signals.

142 Changes in MSE occur with changes in spectral power (Lippé et al., 2009; McIntosh
143 et al., 2008) so we additionally assessed spectral power (SPD) alongside MSE. SPD was
144 calculated for each trial using the fast Fourier transform with a Hann window. To account
145 for age-related global signal power changes, each recording was first normalized (mean = 0,
146 $SD = 1$). Relative spectral power was then calculated for each trial, and results averaged
147 across trials to acquire mean SPD per channel for each subject.

148 **Partial Least Squares Analysis**


149 MSE and SPD measures were each correlated with the available demographic and clinical
150 data using a Partial Least Squares (PLS) analysis (Krishnan et al., 2011; McIntosh and
151 Lobaugh, 2004). This multivariate statistical approach identifies a set of latent variables
152 (LVs) that represent the maximal covariance between two datasets. First, the correlation
153 between the MSE/SPD and clinical data was computed across subjects. Singular value
154 decomposition was then performed on the correlation matrix to produce LVs, each
155 containing three elements: 1) a set of weighted “salience” that describe a spatiotemporal
156 brain pattern of MSE/SPD measures; 2) a scalar singular value that expresses the strength of
157 the covariance; and 3) a design contrast of correlation coefficients that express how the
158 clinical data relate to the saliences. The mutually orthogonal LVs are extracted in order of
159 magnitude, whereby the first LV explains the most covariance between MSE/SPD and clinical

160 data, the second LV the second most, and so forth. The significance of each LV was assessed
161 with permutation testing by randomly reordering subjects' MSE/SPD pairing with clinical
162 data to produce 1000 permuted sets for singular value decomposition, with the set of 1000
163 singular values forming the null distribution. The reliability of the MSE/SPD at each
164 electrode in expressing the covariance pattern of each LV was assessed using bootstrap
165 resampling. A set of 500 bootstrap samples was created by resampling subjects with
166 replacement. The ratio between the saliences and the estimated standard error (bootstrap
167 ratio) was taken as an index of reliability. With the assumption that the bootstrap
168 distribution is normal, the bootstrap ratio is akin to a Z-score and corresponding saliences
169 are considered to be reliable if the absolute value of their bootstrap ratio is ≥ 2 . For the
170 clinical data, confidence intervals were calculate from the upper and lower bounds of the
171 95th percentile of the bootstrap distribution of the correlation with the scores from the
172 MSE/SPD data. The scores are the dot-product of the saliences with the data for each subject
173 and are similar to a factor score from factor analysis.

174 For the demographic and clinical data entered into the PLS analysis, age and number
175 of non-brain medications were treated as continuous variables, while all other variables
176 were categorical. Sex was coded as 0 (F) and 1 (M). The remaining variables were coded as
177 0 (not on drug or does not have condition) or 1 (on drug or has condition).

178 Results


179 To determine whether different and heterogeneous clinical profiles can result in differences
180 in brain signal complexity, MSE curves for each subject were correlated with their
181 demographic and clinical data using a PLS analysis. The singular value decomposition of the
182 correlation matrix resulted in two significant LVs. The first LV showed a differentiation
183 between brain disorders, with a global shift towards greater signal complexity in finer time
184 scales and lower signal complexity in coarser time scales across all electrodes for subjects
185 who experienced generalized seizures or those taking antidepressants as compared to those
186 with other brain conditions (i.e., focal seizures, stroke, neurodevelopmental disorders) or
187 using other medications (i.e., anti-epileptics, barbiturates) (Fig. 1A-B). This shift in MSE was
188 evident when a median-split was performed to classify subjects according to how much they
189 expressed the patterns of the LV (i.e., a median split of the LV-scores, Fig. 1C). This LV was
190 significant ($p < 0.001$) and accounted for 57.8% of the covariance in the data.



191
192 **Figure 1. Brain signal complexity differentiates brain disorders.** (A) Correlation coefficients and (B) bootstrap ratios
193 of the first latent variable relating clinical data to MSE curves. (C) Average (\pm SEM) MSE curves, with subjects split
194 into two groups according to their LV-scores. MSE curves were first averaged across electrodes within subjects, then
195 averaged across subjects within each group. In (A), variables whose coefficients are significantly different from 0 are
196 indicated in color for ease of interpretation.


197 The second LV differentiated older unhealthy (as indexed by the number of non-
198 brain-related medications taken) males who did not have neurodegenerative disease from
199 other subjects, and was associated with slightly higher entropy at the very finest scales and
200 lower brain signal complexity across more coarse time scales (Fig. 2). This LV was significant
201 ($p < 0.01$) and accounted for 29.0% of the covariance in the data.

202
203



204
205 **Figure 2. Brain signal complexity differs for older unhealthy males.** Correlation coefficients (A) and bootstrap ratios
206 (B) of the second latent variable relating clinical data to MSE curves. (C) Average (\pm SEM) MSE curves, with subjects
207 split into two groups according to their LV-scores. MSE curves were first averaged across electrodes within subjects,
208 then averaged across subjects within each group. In (A), variables whose coefficients are significantly different from
209 0 are indicated in color for ease of interpretation.

210 The MSE profiles for each of the latent variables therefore reflected a unique
211 timescale-dependent shift in brain signal complexity associated with different brain and
212 non-brain disorders. A similar analysis of SPD indicated that SPD profiles could only
213 differentiate between subjects with epilepsy from those without epilepsy (Figure 3).



214
 215 **Figure 3. Spectral power density differentiates epilepsy from other brain disorders.** (A) First latent
 216 variable ($p < 0.001$; 50.1% covariance explained) (B) second latent variable ($p < 0.001$; 29.9% covariance
 217 explained), and (C) third latent variable ($p = 0.068$; 10.1% covariance explained) of a PLS analysis relating
 218 clinical data to SPD. Left panels: correlation coefficients; middle panels: bootstrap ratios; right panels: average
 219 (\pm SEM) SPD, with subjects split into two groups according to their LV-scores. SPD functions were first averaged
 220 across electrodes within subjects, then averaged across subjects within each group.

221 **Discussion**

222 In this study, we examined whether brain signal complexity varied across individuals of a
223 large and heterogeneous clinical population using a data driven approach. We found
224 timescale-dependent differences in brain signal complexity for individuals who experience
225 generalized seizures from individuals who have other brain disorders (e.g., focal seizures,
226 stroke, neurodevelopmental disorders). We also found a timescale-dependent shift in brain
227 signal complexity for older males on various medications not related to neurological or
228 neurodegenerative disease that was not evident in the spectral power of the clinical-EEG
229 recordings. Our findings suggest that brain signal complexity, as indexed by MSE, can provide
230 additional insights into brain health status and function not captured by spectral power.

231 In line with the notion that the brain is a dynamical system in which “noise” allows
232 for flexible functioning and a variety of metastable states (Deco et al., 2017, 2011), MSE can
233 be considered as an index of functional repertoire (Heisz et al., 2012). Changes to brain
234 function and dynamics can occur with neurological disease and, indeed, differences in MSE
235 from matched controls have been reported for both epilepsy (Weng et al., 2015) and
236 neurodegenerative disease (Tsai et al., 2015). Here we build on these previous reports by
237 showing how the changes in MSE in these neurological conditions can be differentiated from
238 each other. A complementary data-driven analysis of SPD showed changes in power across
239 frequency bands that differentiated epilepsy from all other diagnoses as well as generalized
240 from focal seizures, consistent with numerous accounts of SPD differences in epilepsy
241 (Clemens et al., 2000; Díaz et al., 1998; Niso et al., 2015; Quraan et al., 2013; Walker, 2008).
242 However, the differentiation of individuals with non-neurological comorbidities was unique
243 to MSE.

244 The MSE results also replicate previous observations that the scale-dependent changes are
245 indicative of neurodegenerative disorders (Figure 2). Higher MSE at coarse-scales was
246 shown to predict cognitive decline in Parkinson's patients who would develop dementia
247 (Bertrand et al., 2016). The relative balance within subjects between fine and coarse scales
248 also relates to cognitive status in aging (Heisz et al., 2015). These results, considered in the
249 context of the present data, suggest that the relative shifts of complexity across temporal
250 scales may be a sensitive index to assist in clinical evaluation, particular as a predictor of
251 future cognitive decline (McIntosh, 2019).

252 Metabolic diseases such as diabetes mellitus are known to affect brain structure and
253 cognitive function (Soininen et al., 1992; Tan et al., 2011). More recently, changes to resting-
254 state functional networks have been observed in individuals with diabetes mellitus
255 compared to controls (Y. F. Wang et al., 2016). Autonomic dysfunction, such as hypertension
256 and heart failure, is also a well-documented risk factor for cognitive impairment
257 (Alagiakrishnan et al., 2016; Cannon et al., 2017; Meissner, 2016) and has been associated
258 with changes to brain structure (Kumar et al., 2015; Moon et al., 2018; Suzuki et al., 2017)
259 and function (Bu et al., 2018; Li et al., 2015; Park et al., 2016). As such, both diabetes mellitus
260 and hypertension have been linked to neurological disorders such as stroke (Turin et al.,
261 2016) and dementia (Ninomiya, 2014). One previous report has shown how hypoglycemic
262 conditions in individuals with Type 1 diabetes mellitus results in changes to brain signal MSE
263 (Fabris et al., 2014). We extend these previous findings by showing that the effects of various
264 non-neurological diseases on the brain can be detected by MSE. Together with evidence that
265 MSE changes in response to medical therapies (Farzan et al., 2017; Jaworska et al., 2018;

266 Liang et al., 2014; Okazaki et al., 2015), MSE offers a promising avenue for the development
267 of clinical biomarkers.

268 **Acknowledgments**

269 This research was supported by a grant from the J. S. McDonnell Foundation to A. R. M.

270 **CRedit Author Statement**

271 **Kelly Shen:** Conceptualization, Software, Formal Analysis, Validation, Visualization, Writing
272 – Original Draft **Alison McFadden:** Data Curation, Software, Formal Analysis **Anthony R.**
273 **McIntosh:** Conceptualization, Methodology, Writing – Review & Editing, Supervision,
274 Funding Acquisition

275 **Disclosure Statement**

276 The authors have no competing interests to declare.

277 **References**

- 278 Alagiakrishnan, K., Mah, D., Ahmed, A., Ezekowitz, J., 2016. Cognitive decline in heart failure.
279 Heart Fail. Rev. 21, 661–673. <https://doi.org/10.1007/s10741-016-9568-1>
- 280 Berg, A.T., Berkovic, S.F., Brodie, M.J., Buchhalter, J., Cross, J.H., Van Emde Boas, W., Engel, J.,
281 French, J., Glauser, T.A., Mathern, G.W., Moshé, S.L., Nordli, D., Plouin, P., Scheffer, I.E.,
282 2010. Revised terminology and concepts for organization of seizures and epilepsies:
283 Report of the ILAE Commission on Classification and Terminology, 2005-2009.
284 Epilepsia. <https://doi.org/10.1111/j.1528-1167.2010.02522.x>
- 285 Bertrand, J.-A., McIntosh, A.R., Postuma, R.B., Kovacevic, N., Latreille, V., Panisset, M.,
286 Chouinard, S., Gagnon, J.-F., 2016. Brain Connectivity Alterations Are Associated with
287 the Development of Dementia in Parkinson’s Disease. Brain Connect. 6, 216–224.
288 <https://doi.org/10.1089/brain.2015.0390>
- 289 Blume, W.T., Lüders, H.O., Mizrahi, E., Tassinari, C., Van Emde Boas, W., Engel, J., 2001.
290 Glossary of descriptive terminology for ictal semiology: Report of the ILAE Task Force
291 on classification and terminology. Epilepsia. [https://doi.org/10.1046/j.1528-](https://doi.org/10.1046/j.1528-1157.2001.22001.x)
292 [1157.2001.22001.x](https://doi.org/10.1046/j.1528-1157.2001.22001.x)
- 293 Bu, L., Huo, C., Xu, G., Liu, Y., Li, Z., Fan, Y., Li, J., 2018. Alteration in Brain Functional and
294 Effective Connectivity in Subjects With Hypertension. Front. Physiol. 9, 669.
295 <https://doi.org/10.3389/fphys.2018.00669>
- 296 Cannon, J.A., Moffitt, P., Perez-Moreno, A.C., Walters, M.R., Broomfield, N.M., McMurray, J.J.V.,
297 Quinn, T.J., 2017. Cognitive Impairment and Heart Failure: Systematic Review and Meta-
298 Analysis. J. Card. Fail. 23, 464–475. <https://doi.org/10.1016/j.cardfail.2017.04.007>
- 299 Clemens, B., Szigeti, G., Barta, Z., 2000. EEG frequency profiles of idiopathic generalised

300 epilepsy syndromes. *Epilepsy Res.* 42, 105–15.

301 Costa, M., Goldberger, A.L., Peng, C., 2002. Multiscale Entropy Analysis of Complex
302 Physiologic Time Series 6–9. <https://doi.org/10.1103/PhysRevLett.89.068102>

303 Costa, M., Goldberger, A.L., Peng, C.K., 2005. Multiscale entropy analysis of biological signals.
304 *Phys. Rev. E - Stat. Nonlinear, Soft Matter Phys.* 71.
305 <https://doi.org/10.1103/PhysRevE.71.021906>

306 Deco, G., Jirsa, V.K., McIntosh, A.R., 2011. Emerging concepts for the dynamical organization
307 of resting-state activity in the brain. *Nat. Rev. Neurosci.* 12, 43–56.
308 <https://doi.org/10.1038/nrn2961>

309 Deco, G., Kringelbach, M.L., Jirsa, V.K., Ritter, P., 2017. The dynamics of resting fluctuations in
310 the brain: metastability and its dynamical cortical core. *Sci. Rep.* 7, 3095.
311 <https://doi.org/10.1038/s41598-017-03073-5>

312 Díaz, G.F., Virués, T., San Martín, M., Ruiz, M., Galán, L., Paz, L., Valdés, P., Díaz, G., Virués, T.,
313 San Martín, M., Ruiz, M., Galán, L., Paz, L., Valdés, P., 1998. Generalized background qEEG
314 abnormalities in localized symptomatic epilepsy. *Electroencephalogr. Clin.*
315 *Neurophysiol.* 106, 501–7. [https://doi.org/10.1016/s0013-4694\(98\)00026-1](https://doi.org/10.1016/s0013-4694(98)00026-1)

316 Fabris, C., Sparacino, G., Sejling, A.-S., Goljahani, A., Duun-Henriksen, J., Remvig, L.S., Juhl, C.B.,
317 Cobelli, C., 2014. Hypoglycemia-Related Electroencephalogram Changes Assessed by
318 Multiscale Entropy. *Diabetes Technol. Ther.* 16, 688–694.
319 <https://doi.org/10.1089/dia.2013.0331>

320 Farzan, F., Atluri, S., Mei, Y., Moreno, S., Levinson, A.J., Blumberger, D.M., Daskalakis, Z.J., 2017.
321 Brain temporal complexity in explaining the therapeutic and cognitive effects of seizure
322 therapy. *Brain* 140, 1011–1025. <https://doi.org/10.1093/brain/awx030>

- 323 Garrett, D.D., Epp, S.M., Perry, A., Lindenberger, U., 2018. Local temporal variability reflects
324 functional integration in the human brain. *Neuroimage* 183, 776–787.
325 <https://doi.org/10.1016/j.neuroimage.2018.08.019>
- 326 Grieder, M., Wang, D.J.J., Dierks, T., Wahlund, L.-O., Jann, K., 2018. Default Mode Network
327 Complexity and Cognitive Decline in Mild Alzheimer’s Disease. *Front. Neurosci.* 12, 770.
328 <https://doi.org/10.3389/fnins.2018.00770>
- 329 Hager, B., Yang, A.C., Brady, R., Meda, S., Clementz, B., Pearlson, G.D., Sweeney, J.A., Tamminga,
330 C., Keshavan, M., 2017. Neural complexity as a potential translational biomarker for
331 psychosis. *J. Affect. Disord.* 216, 89–99. <https://doi.org/10.1016/j.jad.2016.10.016>
- 332 Hasegawa, C., Takahashi, T., Yoshimura, Y., Nobukawa, S., Ikeda, T., Saito, D.N., Kumazaki, H.,
333 Minabe, Y., Kikuchi, M., 2018. Developmental Trajectory of Infant Brain Signal
334 Variability: A Longitudinal Pilot Study. *Front. Neurosci.* 12, 566.
335 <https://doi.org/10.3389/fnins.2018.00566>
- 336 Heisz, J.J., Gould, M., McIntosh, A.R., 2015. Age-related shift in neural complexity related to
337 task performance and physical activity. *J. Cogn. Neurosci.* 27, 605–13.
338 https://doi.org/10.1162/jocn_a_00725
- 339 Heisz, J.J., Shedden, J.M., McIntosh, A.R., 2012. Relating brain signal variability to knowledge
340 representation. *Neuroimage* 63, 1384–1392.
341 <https://doi.org/10.1016/j.neuroimage.2012.08.018>
- 342 Jaworska, N., Wang, H., Smith, D.M., Blier, P., Knott, V., Protzner, A.B., 2018. Pre-treatment
343 EEG signal variability is associated with treatment success in depression. *NeuroImage.*
344 *Clin.* 17, 368–377. <https://doi.org/10.1016/j.nicl.2017.10.035>
- 345 Jeste, S.S., Frohlich, J., Loo, S.K., 2015. Electrophysiological biomarkers of diagnosis and

- 346 outcome in neurodevelopmental disorders. *Curr. Opin. Neurol.* 28, 110–116.
347 <https://doi.org/10.1097/WCO.0000000000000181>
- 348 Krishnan, A., Williams, L.J., McIntosh, A.R., Abdi, H., 2011. Partial Least Squares (PLS)
349 methods for neuroimaging: A tutorial and review. *Neuroimage* 56, 455–475.
350 <https://doi.org/10.1016/j.neuroimage.2010.07.034>
- 351 Kumar, R., Yadav, S.K., Palomares, J.A., Park, B., Joshi, S.H., Ogren, J.A., Macey, P.M., Fonarow,
352 G.C., Harper, R.M., Woo, M.A., 2015. Reduced Regional Brain Cortical Thickness in
353 Patients with Heart Failure. *PLoS One* 10, e0126595.
354 <https://doi.org/10.1371/journal.pone.0126595>
- 355 Li, X., Liang, Y., Chen, Y., Zhang, J., Wei, D., Chen, K., Shu, N., Reiman, E.M., Zhang, Z., 2015.
356 Disrupted Frontoparietal Network Mediates White Matter Structure Dysfunction
357 Associated with Cognitive Decline in Hypertension Patients. *J. Neurosci.* 35, 10015–
358 10024. <https://doi.org/10.1523/JNEUROSCI.5113-14.2015>
- 359 Liang, W.-K., Lo, M.-T., Yang, A.C., Peng, C.-K., Cheng, S.-K., Tseng, P., Juan, C.-H., 2014.
360 Revealing the brain's adaptability and the transcranial direct current stimulation
361 facilitating effect in inhibitory control by multiscale entropy. *Neuroimage* 90, 218–234.
362 <https://doi.org/10.1016/j.neuroimage.2013.12.048>
- 363 Lippé, S., Kovacevic, N., McIntosh, A.R., 2009. Differential maturation of brain signal
364 complexity in the human auditory and visual system. *Front. Hum. Neurosci.* 3, 48.
365 <https://doi.org/10.3389/neuro.09.048.2009>
- 366 Lu, W.-Y., Chen, J.-Y., Chang, C.-F., Weng, W.-C., Lee, W.-T., Shieh, J.-S., 2015. Multiscale
367 Entropy of Electroencephalogram as a Potential Predictor for the Prognosis of Neonatal
368 Seizures. *PLoS One* 10, e0144732. <https://doi.org/10.1371/journal.pone.0144732>

- 369 McIntosh, A.R., 2019. Neurocognitive Aging and Brain Signal Complexity, in: Oxford Research
370 Encyclopedia of Psychology. Oxford University Press, pp. 1–25.
371 <https://doi.org/10.1093/acrefore/9780190236557.013.386>
- 372 McIntosh, A.R., Kovacevic, N., Itier, R.J., 2008. Increased brain signal variability accompanies
373 lower behavioral variability in development. *PLoS Comput. Biol.* 4.
374 <https://doi.org/10.1371/journal.pcbi.1000106>
- 375 McIntosh, A.R., Lobaugh, N.J., 2004. Partial least squares analysis of neuroimaging data:
376 applications and advances. *Neuroimage* 23 Suppl 1, S250-63.
377 <https://doi.org/10.1016/j.neuroimage.2004.07.020>
- 378 McIntosh, A.R., Vakorin, V., Kovacevic, N., Wang, H., Diaconescu, A., Protzner, A.B., 2014.
379 Spatiotemporal dependency of age-related changes in brain signal variability. *Cereb.*
380 *Cortex* 24, 1806–1817. <https://doi.org/10.1093/cercor/bht030>
- 381 Meissner, A., 2016. Hypertension and the Brain: A Risk Factor for More Than Heart Disease.
382 *Cerebrovasc. Dis.* 42, 255–262. <https://doi.org/10.1159/000446082>
- 383 Mišić, B., Doesburg, S.M., Fatima, Z., Vidal, J., Vakorin, V.A., Taylor, M.J., McIntosh, A.R., 2015.
384 Coordinated Information Generation and Mental Flexibility: Large-Scale Network
385 Disruption in Children with Autism. *Cereb. Cortex* 25, 2815–2827.
386 <https://doi.org/10.1093/cercor/bhu082>
- 387 Misić, B., Mills, T., Taylor, M.J., McIntosh, A.R., 2010. Brain noise is task dependent and region
388 specific. *J. Neurophysiol.* 104, 2667–2676. <https://doi.org/10.1152/jn.00648.2010>
- 389 Miskovic, V., Owens, M., Kuntzleman, K., Gibb, B.E., 2016. Charting Moment-to-Moment Brain
390 Signal Variability From Early to Late Childhood. *Cortex.* 83, 51.
391 <https://doi.org/10.1016/J.CORTEX.2016.07.006>

- 392 Moon, C., Melah, K.E., Johnson, S.C., Bratzke, L.C., 2018. Sleep-disordered breathing, brain
393 volume, and cognition in older individuals with heart failure. *Brain Behav.* 8, e01029.
394 <https://doi.org/10.1002/brb3.1029>
- 395 Ninomiya, T., 2014. Diabetes Mellitus and Dementia. *Curr. Diab. Rep.* 14, 487.
396 <https://doi.org/10.1007/s11892-014-0487-z>
- 397 Niso, G., Carrasco, S., Gudín, M., Maestú, F., del-Pozo, F., Pereda, E., 2015. What graph theory
398 actually tells us about resting state interictal MEG epileptic activity. *NeuroImage Clin.* 8,
399 503–515. <https://doi.org/10.1016/j.nicl.2015.05.008>
- 400 Niu, Y., Wang, B., Zhou, M., Xue, J., Shapour, H., Cao, R., Cui, X., Wu, J., Xiang, J., 2018. Dynamic
401 Complexity of Spontaneous BOLD Activity in Alzheimer’s Disease and Mild Cognitive
402 Impairment Using Multiscale Entropy Analysis. *Front. Neurosci.* 12, 677.
403 <https://doi.org/10.3389/fnins.2018.00677>
- 404 Obeid, I., Picone, J., 2016. The Temple University Hospital EEG Data Corpus. *Front. Neurosci.*
405 10, 196. <https://doi.org/10.3389/fnins.2016.00196>
- 406 Okazaki, R., Takahashi, T., Ueno, K., Takahashi, K., Ishitobi, M., Kikuchi, M., Higashima, M.,
407 Wada, Y., 2015. Changes in EEG Complexity with Electroconvulsive Therapy in a Patient
408 with Autism Spectrum Disorders: A Multiscale Entropy Approach. *Front. Hum. Neurosci.*
409 9, 106. <https://doi.org/10.3389/fnhum.2015.00106>
- 410 Oostenveld, R., Fries, P., Maris, E., Schoffelen, J.-M., 2011. FieldTrip: Open source software for
411 advanced analysis of MEG, EEG, and invasive electrophysiological data. *Comput. Intell.*
412 *Neurosci.* 2011, 156869. <https://doi.org/10.1155/2011/156869>
- 413 Park, B., Roy, B., Woo, M.A., Palomares, J.A., Fonarow, G.C., Harper, R.M., Kumar, R., 2016.
414 Lateralized Resting-State Functional Brain Network Organization Changes in Heart

- 415 Failure. PLoS One 11, e0155894. <https://doi.org/10.1371/journal.pone.0155894>
- 416 Quraan, M.A., McCormick, C., Cohn, M., Valiante, T.A., McAndrews, M.P., 2013. Altered resting
417 state brain dynamics in temporal lobe epilepsy can be observed in spectral power,
418 functional connectivity and graph theory metrics. PLoS One 8, e68609.
419 <https://doi.org/10.1371/journal.pone.0068609>
- 420 Raja Beharelle, A., Kovačević, N., McIntosh, A.R., Levine, B., Beharelle, A.R., Kovačević, N.,
421 McIntosh, A.R., Levine, B., Raja Beharelle, A., Kovačević, N., McIntosh, A.R., Levine, B.,
422 2012. Brain signal variability relates to stability of behavior after recovery from diffuse
423 brain injury. Neuroimage 60, 1528–1537.
424 <https://doi.org/10.1016/j.neuroimage.2012.01.037>
- 425 Richman, J.S., Moorman, J.R., 2000. Physiological time-series analysis using approximate
426 entropy and sample entropy. Am. J. Physiol. Circ. Physiol. 278, H2039–H2049.
427 <https://doi.org/10.1152/ajpheart.2000.278.6.H2039>
- 428 Sleimen-Malkoun, R., Perdikis, D., Müller, V., Blanc, J.-L., Huys, R., Temprado, J.-J., Jirsa, V.K.,
429 2015. Brain Dynamics of Aging: Multiscale Variability of EEG Signals at Rest and during
430 an Auditory Oddball Task. eNeuro 2. <https://doi.org/10.1523/ENEURO.0067-14.2015>
- 431 Soininen, H., Puranen, M., Helkala, E.L., Laakso, M., Riekkinen, P.J., 1992. Diabetes mellitus
432 and brain atrophy: a computed tomography study in an elderly population. Neurobiol.
433 Aging 13, 717–21.
- 434 Suzuki, H., Gao, H., Bai, W., Evangelou, E., Glocker, B., O'Regan, D.P., Elliott, P., Matthews, P.M.,
435 2017. Abnormal brain white matter microstructure is associated with both pre-
436 hypertension and hypertension. PLoS One 12, e0187600.
437 <https://doi.org/10.1371/journal.pone.0187600>

- 438 Szostakiwskyj, J.M.H., Willatt, S.E., Cortese, F., Protzner, A.B., 2017. The modulation of EEG
439 variability between internally- and externally-driven cognitive states varies with
440 maturation and task performance. *PLoS One* 12, e0181894.
441 <https://doi.org/10.1371/journal.pone.0181894>
- 442 Takahashi, T., 2013. Complexity of spontaneous brain activity in mental disorders. *Prog.*
443 *Neuro-Psychopharmacology Biol. Psychiatry* 45, 258–266.
444 <https://doi.org/10.1016/j.pnpbp.2012.05.001>
- 445 Takahashi, T., Yoshimura, Y., Hiraishi, H., Hasegawa, C., Munesue, T., Higashida, H., Minabe,
446 Y., Kikuchi, M., 2016. Enhanced brain signal variability in children with autism spectrum
447 disorder during early childhood. *Hum. Brain Mapp.* 37, 1038–50.
448 <https://doi.org/10.1002/hbm.23089>
- 449 Tan, Z.S., Beiser, A.S., Fox, C.S., Au, R., Himali, J.J., DeBette, S., DeCarli, C., Vasan, R.S., Wolf, P.A.,
450 Seshadri, S., 2011. Association of Metabolic Dysregulation With Volumetric Brain
451 Magnetic Resonance Imaging and Cognitive Markers of Subclinical Brain Aging in
452 Middle-Aged Adults. *Diabetes Care* 34, 1766–1770. [https://doi.org/10.2337/dc11-](https://doi.org/10.2337/dc11-0308)
453 0308
- 454 Tsai, P.-H., Chang, S.-C., Liu, F.-C., Tsao, J., Wang, Y.-H., Lo, M.-T., 2015. A Novel Application of
455 Multiscale Entropy in Electroencephalography to Predict the Efficacy of
456 Acetylcholinesterase Inhibitor in Alzheimer’s Disease. *Comput. Math. Methods Med.*
457 2015, 1–8. <https://doi.org/10.1155/2015/953868>
- 458 Turin, T.C., Okamura, T., Afzal, A.R., Rumana, N., Watanabe, M., Higashiyama, A., Nakao, Y.,
459 Nakai, M., Takegami, M., Nishimura, K., Kokubo, Y., Okayama, A., Miyamoto, Y., 2016.
460 Hypertension and lifetime risk of stroke. *J. Hypertens.* 34, 116–122.

- 461 <https://doi.org/10.1097/HJH.0000000000000753>
- 462 Vakorin, V.A., McIntosh, A.R., 2012. Mapping the multi-scale information content of complex
463 brain signals, in: Rabinovich, M., Friston, K.J., Varona, P. (Eds.), Principles of Brain
464 Dynamics: Global State Interactions. MIT Press, Cambridge, Mass., pp. 183–208.
- 465 Walker, J.E., 2008. Power Spectral Frequency and Coherence Abnormalities in Patients with
466 Intractable Epilepsy and Their Usefulness in Long-Term Remediation of Seizures Using
467 Neurofeedback. Clin. EEG Neurosci. 39, 203–205.
468 <https://doi.org/10.1177/155005940803900410>
- 469 Wang, H., McIntosh, A.R., Kovacevic, N., Karachalios, M., Protzner, A.B., 2016. Age-related
470 Multiscale Changes in Brain Signal Variability in Pre-task versus Post-task Resting-state
471 EEG. J. Cogn. Neurosci. 28, 971–984. https://doi.org/10.1162/jocn_a_00947
- 472 Wang, Y.F., Ji, X.M., Lu, G.M., Zhang, L.J., 2016. Resting-state functional MR imaging shed
473 insights into the brain of diabetes. Metab. Brain Dis. 31, 993–1002.
474 <https://doi.org/10.1007/s11011-016-9872-4>
- 475 Weng, W.-C., Chang, C.-F., Wong, L.C., Lin, J.-H., Lee, W.-T., Shieh, J.-S., 2017. Altered resting-
476 state EEG complexity in children with Tourette syndrome: A preliminary study.
477 Neuropsychology 31, 395–402. <https://doi.org/10.1037/neu0000363>
- 478 Weng, W.-C., Jiang, G.J.A., Chang, C.-F., Lu, W.-Y., Lin, C.-Y., Lee, W.-T., Shieh, J.-S., 2015.
479 Complexity of Multi-Channel Electroencephalogram Signal Analysis in Childhood
480 Absence Epilepsy. PLoS One 10, e0134083.
481 <https://doi.org/10.1371/journal.pone.0134083>
- 482 Yang, A.C., Hong, C.-J., Liou, Y.-J., Huang, K.-L., Huang, C.-C., Liu, M.-E., Lo, M.-T., Huang, N.E.,
483 Peng, C.-K., Lin, C.-P., Tsai, S.-J., 2015. Decreased Resting-State Brain Activity Complexity

484 in Schizophrenia Characterized by Both Increased Regularity and Randomness.
485 <https://doi.org/10.1002/hbm.22763>
486 Yang, A.C., Huang, C.-C., Yeh, H.-L., Liu, M.-E., Hong, C.-J., Tu, P.-C., Chen, J.-F., Huang, N.E., Peng,
487 C.-K., Lin, C.-P., Tsai, S.-J., 2013. Complexity of spontaneous BOLD activity in default
488 mode network is correlated with cognitive function in normal male elderly: a multiscale
489 entropy analysis. <https://doi.org/10.1016/j.neurobiolaging.2012.05.004>